← Shanghai Fosun Pharmaceutical overview

Shanghai Fosun Pharmaceutical vs Procept Biorobotics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Procept Biorobotics Corp (PRCT)

Q3 2026
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

July 2026
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

Latest
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.